NICE to approve icosapent ethyl for some high-risk cardiovascular patients - The Pharmaceutical Journal

6/22/2022 12:00:00 AM2 years 10 months ago

The National Institute for Health and Care Excellence (NICE) is set to approve the omega-3 fatty acid icosapent ethyl for reducing heart attacks and strokes for some high-risk patients. In final draft guidance, due to be formally published on 13 July 2022, NI…

The National Institute for Health and Care Excellence (NICE) is set to approve the omega-3 fatty acid icosapent ethyl for reducing heart attacks and strokes for some high-risk patients. In final dra… [+2135 chars]

full article...